VHEST Study
In 2009, Ibn Al-Haytham led VHEST, a post-marketing observational study evaluating the efficacy, safety, and tolerability of Valsartan and Valsartan HCT in managing essential hypertension—not in theory, but in actual clinical practice across Syria.
Study Scope:
- Patients: 1,254
- Participating Doctors: 100
- Setting: Diverse outpatient environments across the country
Efficacy Ratings:
- 67% Excellent
- 24% Good
- 8% Fair
- 1% Poor
Tolerability Ratings:
- 90% Excellent
- 7% Good
- 2% Fair
- 1% Poor
Adverse Event Probability: 5.1%
This study didn’t just measure molecules—it measured lives impacted, trust earned, and clinical realities navigated.
At Ibn Al-Haytham, we believe that credibility isn’t claimed—it’s demonstrated through transparent data, regional relevance, and patient-first insights.